WORLD / Health
First brain cancer vaccine approved in Switzerland
(AFP)
Updated: 2007-07-10 00:32
Northwest Biotherapeutics, a US-based biotech company, said Monday it had
won approval for commercial use of the world's first vaccine against
brain cancer in Switzerland.
A computer image mapping parts of the brain. Northwest Biotherapeutics, a
US-based biotech company, has said it has won approval for commercial use
of the world's first vaccine against brain cancer in Switzerland.[AFP]
The company, which is listed in London, intends to begin making
DCVax-Brain available to patients before the end of September, according
to a statement.
Under the Swiss approval plan, Northwest is able to manufacture the
vaccine in the United States and make it available for the treatment of
patients with brain cancer at select centres in Switzerland.
"We are delighted to be the first company to reach the market with a
personalized therapeutic vaccine for brain cancers, which carry a very
bleak prognosis for patients," said Alton Boynton, president and chief
executive of Northwest Biotherapeutics.
"Switzerland is an attractive place to begin commercialisation, due to
its highly respected regulatory oversight, and its growing experience
with cellular therapies.
Boynton added: "We look forward to being able to bring DCVax-Brain to
patients in additional countries, and to applying our DCVax technology to
many other cancers."
Top World News
� 4 convicted in failed UK transit plot
� Arab League plans first Israel mission
� UK terror chief warns of long fight
� Iraq al-Qaida group threatens Iran
� 335 religious students killed in Pakistan
Today's Top News
� HIV-positive convicts: Prisoners of prejudice
� Legal interpretation targets bribery
� Three Chinese killed in Pakistan
� 4 convicted in failed UK transit plot
� Central banker: Monetary policies won't target stocks and properties
Most Commented/Read Stories in 48 Hours
No comments:
Post a Comment